JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M200335200 on February 1, 2002

J. Biol. Chem., Vol. 277, Issue 19, 17320-17326, May 10, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/19/17320    most recent
M200335200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fratti, R. A.
Right arrow Articles by Deretic, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fratti, R. A.
Right arrow Articles by Deretic, V.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Cellubrevin Alterations and Mycobacterium tuberculosis Phagosome Maturation Arrest*

Rutilio A. FrattiDagger §, Jennifer ChuaDagger §, and Vojo Deretic§||**

From the Dagger  Department of Microbiology and Immunology and  Program in Cellular and Molecular Biology, University of Michigan Medical School, Ann Arbor, Michigan and the Departments of § Molecular Genetics and Microbiology and || Cell Biology and Physiology, University of New Mexico School of Medicine, Albuquerque, New Mexico 87131

Received for publication, January 11, 2002, and in revised form, January 30, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The intracellular trafficking processes controlling phagosomal maturation remain to be fully delineated. Mycobacterium tuberculosis var. bovis BCG, an organism that causes phagosomal maturation arrest, has emerged as a tool for dissection of critical phagosome biogenesis events. In this work, we report that cellubrevin, a v-SNARE functioning in endosomal recycling and implicated in endosomal interactions with post-Golgi compartments, plays a role in phagosomal maturation and that it is altered on mycobacterial phagosomes. Both mycobacterial phagosomes, which undergo maturation arrest, and model phagosomes containing latex beads, which follow the normal pathway of maturation into phagolysosomes, acquired cellubrevin. However, the mycobacterial and model phagosomes differed, as a discrete proteolytic degradation of this SNARE was detected on mycobacterial phagosomes. The observed cellubrevin alteration on mycobacterial phagosomes was not a passive event secondary to a maturation arrest at another checkpoint of the phagosome maturation pathway, since pharmacological inhibitors of phagosomal/endosomal pathways blocking phagosomal maturation did not cause cellubrevin degradation on model phagosomes. Cellubrevin status on phagosomes had consequences on phagosomal membrane and lumenal content trafficking, involving plasma membrane marker recycling and delivery of lysosomal enzymes. These results suggest that cellubrevin plays a role in phagosomal maturation and that it is a target for modification by mycobacteria or by infection-induced processes in the host cell.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The mechanisms of phagosomal biogenesis and maturation into the phagolysosome represent a fundamental biological process reflecting regulatory aspects of membrane trafficking and organelle biogenesis in eukaryotic cells (1-9). These processes are sometimes targeted by a class of microbes capable of affecting phagosome integrity or maturation (8, 10-19). Interference with the normal pathway of phagosomal maturation into the phagolysosome enables such intracellular pathogens to avoid microbial growth control or killing by the host phagocytic cells or to avert efficient antigen presentation to the effectors of adaptive immune response in the host (1, 3, 7, 20, 21). Consequently, investigations of microbial interference with the trafficking processes in the host cells may provide a means for dissecting the phagosomal maturation pathway. In this context, we have been using Mycobacterium tuberculosis, a highly adapted pathogen that parasitizes macrophages, as a tool to study fundamental phagosome maturation processes (reviewed in Ref. 22). It has been established that M. tuberculosis, M. tuberculosis var. bovis BCG, and Mycobacterium avium reside in specialized phagosomes that afford protection from acquisition of the characteristics of the terminal lysosomal organelles (23-26), a phenomenon termed in classical microbiological literature as the inhibition of phagosome-lysosome fusion (27). The unique distribution of markers on M. tuberculosis phagosomal compartments (MPC)1 suggests that there may be discrete alterations in MPC interactions with other intracellular organelles (22). Mycobacterial phagosomes display reduced clearance of early phagosomal proteins such as TACO (28), better known as Coronin (22, 28), and several plasma membrane markers (24); they manifest impaired acidification due to the paucity of H+ATPase (29); and they show limited acquisition of late endosomal/lysosomal proteins (23, 30, 31).

Membrane trafficking, organelle biogenesis, and maintenance of compartmental integrity are highly regulated processes and depend on a multicomponent vesicle docking and fusion machinery. The basal apparatus needed in the final stages of membrane fusion is composed of SNARE proteins forming a four-helix trans-SNARE bundle contributed by the donor and acceptor membranes (32). Prior to a fusion event, the pre-existing cis-SNARE complexes are disassembled and primed by the action of the ATPase NSF and alpha -SNAP, preparing the fusion proteins for the formation of trans-SNARE pairing (33, 34). Purified, fusion competent SNAREs (32, 35-38), in combination with other tethering and regulatory factors such as Rab GTPases and their effectors (39-43), define the permissive fusion events in vivo.

In this work, we extended our analyses of the phagosomal organelles to the v-SNARE cellubrevin. Cellubrevin (also known as VAMP3) is a SNARE molecule involved in the recycling of plasma membrane markers from the endosome (44) and has been implicated in trafficking from the TGN to the endocytic pathway through interactions with the TGN SNARE Syntaxin 6 (45). Here we report the degradation of cellubrevin on the M. tuberculosis phagosome, as a mechanism contributing to altered trafficking from and to the mycobacterial phagosome.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cell and Bacterial Culture Conditions-- The murine macrophage-like cell line, J774, was maintained in Dulbecco's modified Eagle's medium (BioWhittaker) supplemented with 4 mM L-glutamine and 5% fetal bovine serum (HyClone). M. tuberculosis var. bovis BCG Pasteur (BCG) harboring phsp60-gfp was grown in Middlebrook 7H9 broth (46). Single cell suspensions were generated using a Tenbroek tissue grinder, followed by a 5-min pulse in a water bath sonicator. Remaining bacterial aggregates were removed by low speed centrifugation.

Phagosome Purification-- For experiments examining brief infection periods (<1 h), infections were synchronized as described previously (8). Synchronization of latex beads and BCG phagocytosis was achieved by allowing latex beads or BCG to attach to macrophages cooled to 4 °C without allowing uptake. Samples were shifted to 37 °C for various periods of time and phagosomes isolated as described previously. For longer phagosome chase experiments, BCG or latex beads were taken up by macrophages for 1 h, followed by removal of unphagocytosed particles and fresh media added for 1 to 24 h (19). Phagosomes were isolated and characterized for purity as described previously (19). Briefly, cells were mechanically lysed in 8.5% sucrose (w/w in homogenization buffer: 1 mM HEPES, pH 7.0, 0.5 mM EGTA, 1 mM EDTA, 1 mg/ml bovine gelatin) supplemented with protease inhibitors. After cellular debris and nuclei were removed by low speed centrifugation to generate post-nuclear supernatants (PNS), PNS from different samples were sedimented by centrifugation through a sucrose step gradient of 8.5, 15, and 50% sucrose (w/w in homogenization buffer). The sediment collected from the 15/50% interface was loaded on a linear 32-53% sucrose gradient (w/w in homogenization buffer). After isopycnic separation of organelles, fractions were collected from the top of the gradients, and membranes were pelleted. The fraction containing purified MPC were characterized for purity as described previously (19). For latex bead phagosome purification, J774 cells were infected with latex beads and incubated as indicated above. Latex bead phagosomal compartments (LBC) were isolated from PNS by flotation and characterized for purity as described previously (47).

Treatment with Inhibitors-- Prior to infection, cells were treated with 5 µg/ml brefeldin A (Epicentre Technologies) (48), 25 nM bafilomycin A (Sigma) (49) or 10 µM nocodozole (Sigma) (50) for 1 or 2 h at 37 °C or 20 min at 4 °C, respectively. All treatments remained throughout the experiment.

Gel Electrophoresis and Western Blot Analysis-- Equivalent amounts of MPC and LBC (5 µg of protein per well) were separated by 12.5% SDS-PAGE and were transferred to Immobilon-P membranes by electroblotting. For immunoblots, membranes were incubated with antibodies against globular actin (Sigma), AP3 (sigma 3 subunit; from J. Bonifacino and E. Dell'Angelica, National Institutes of Health, Bethesda, MD), cellubrevin (from P. DeCamilli, Yale University, New Haven, CT), LAMP 2 (Developmental Hybridoma Bank), NSF (from S. Whiteheart, University of Kentucky, Lexington, KY), Rab 5 (from L. Huber, Research Institute of Molecular Pathology, Vienna, Austria), SNAP 23 (from P. Roche, NIH, Bethesda, MD), alpha -SNAP (StressGen), Syntaxin 13 (from R. Scheller and R. Prekeris, Stanford University, Palo Alto, CA), Coronin/TACO (from J. Pieters, Basel Institute, Basel, Switzerland), transferrin receptor (BIOSOURCE International), and VAMP1-3 (VAMP c10.1; Synaptic Systems GmbH). Bound antibodies were visualized using the ECL Western blotting system (PerkinElmer Life Sciences). When comparing MPC and LBC on discontinuous membranes, antibody incubations and ECL reactions were performed simultaneously. Membranes were exposed to film simultaneously, and identical exposure times were used.

Statistical Analysis-- All statistical analyses were calculated using Fisher's Protected LSD post hoc test (ANOVA) (SuperANOVA 1.11, Abacus Concepts, Inc.). p values of <= 0.05 were considered significant.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Modifications of the SNARE Cellubrevin on Mycobacterial Phagosomes-- Purified phagosomes containing M. bovis BCG (BCG) or latex beads were prepared and characterized as described previously (8, 19) and examined for the presence and dynamics of endosomal SNAREs. The most striking observation was made with the v-SNARE cellubrevin (VAMP3). Purified LBC were found to contain and accumulate cellubrevin over time (Fig. 1). Surprisingly, purified MPC, while containing cellubrevin (14 kDa), also displayed a lower molecular mass band (12.2 kDa) (Fig. 1A) that reacted with the cellubrevin antibody directed against the cytoplasmic N terminus of cellubrevin (44). The identity of the lower band as a VAMP was confirmed (Fig. 1B) by using the antibody anti-VAMP c10.1, which recognizes the cytoplasmic alpha -helix of VAMP3 (cellubrevin), as well as VAMP1 and VAMP 2 (51). We conclude that the lower molecular mass polypeptide corresponds to a removal of a 1.8-kDa fragment from the C terminus of cellubrevin. The truncated polypeptide, referred to as Delta cellubrevin, was not present on LBC.


View larger version (43K):
[in this window]
[in a new window]
  		Fig. 1.   Degradation of cellubrevin on mycobacterial phagosomes. A, Western blot analysis of purified LBC and MPC using antibody specific for the N terminus of cellubrevin (VAMP3). Phagosomes were purified as described previously (19, 47) from macrophages infected for 1 h and phagosomes chased for 1 or 24 h. Post-nuclear supernatant (P) was isolated from mock 24-h infections. B, MPC preparation probed with pan-VAMP antibody c10.1 recognizing the SNARE helix in VAMP1, VAMP2, and VAMP3. Note the truncated cellubrevin product (Delta Cellubrevin) in A and B. C, post-nuclear supernatants were generated from mock (M) infected J774 cells or cells infected with an increasing m.o.i. M. bovis BCG for 24 h. LBC, MPC (5 µg of protein each), and post-nuclear supernatant (25 µg) were separated by SDS-PAGE; transferred to Immobilon-P, and membranes were probed with affinity-purified rabbit antibodies against cellubrevin, SNAP 23, and actin or monoclonal antibody to NSF. D, quantitative analysis of cellubrevin and actin by Western blots. Cellubrevin degradation in post-nuclear supernatants, obtained from macrophages infected with an increasing m.o.i. of M. bovis BCG, was quantified after 24 h of infection by analyzing relative image intensities using NIH Image 1.61 (n = 3; *, p < 0.005; **, p = 0.0001; ANOVA).

A decrease in the amount of full-length cellubrevin was seen in PNS from BCG-infected cells with the effect depending on the multiplicity of infection (Fig. 1, C and D). Cellubrevin levels were significantly reduced in macrophages infected at a multiplicity of infections (m.o.i.) of 50 or 100 bacilli per cell (Fig. 1, C and D) (p < 0.005 for m.o.i.50; p = 0.0001 for m.o.i.100, relative to maximum cellubrevin levels; ANOVA). Actin levels were unaffected at all m.o.i. values (Fig. 1D). Delta Cellubrevin in PNS observed from BCG-infected cells could only be detected when membranes were pelleted from PNS and overloaded on SDS-PAGE gels (data not shown).

Delta Cellubrevin Generation Is Limited to Mycobacterial Phagosomes-- To test whether BCG infections can affect cellubrevin in trans, e.g. on latex bead phagosomes in the same macrophages, cells were infected with BCG for 24 h prior to superinfecting with latex beads for an additional 24 h after which LBC were purified as described under "Experimental Procedures." We found that conditioning cells with BCG at levels that did not reduce overall cellular cellubrevin levels in infected cells (Fig. 2, PNS), did not significantly alter cellubrevin levels on LBC (Fig. 2, LBC). Furthermore, Delta cellubrevin was absent from LBC isolated from BGC-conditioned macrophages (Fig. 2). This suggests that the effects of BCG on cellubrevin are not exerted globally within BCG-infected macrophages, but represent a phenomenon specific for the mycobacterial phagosome.


View larger version (32K):
[in this window]
[in a new window]
  		Fig. 2.   Cellubrevin on LBC isolated from cells preinfected with mycobacteria. LBC (1 h phagocytosis, 24 h chase) were isolated from uninfected macrophages or macrophages preinfected with M. bovis BCG (m.o.i., 25:1; 1-h phagocytosis, 24-h chase). LBC were isolated as described in the legend to Fig. 1 and examined by Western blotting. Equivalent amounts (protein) of phagosomes were separated by SDS-PAGE, transferred to Immobilon-P, and probed with antibodies against cellubrevin and LAMP.

Pharmacologically Induced Stagnation of Phagosomal Maturation Does Not Affect Cellubrevin Levels on Phagosomes-- We next examined whether the generation of Delta cellubrevin on MPC is only a secondary phenomenon caused by phagosome maturation arrest or could actively contribute to the arrest. This was addressed by inducing a phagosome maturation block using pharmacological inhibitors of membrane trafficking. We found that treatment with bafilomycin A and nocodozole, two known inhibitors of cellular functions essential in endosome maturation (acidification and microtubule based vectorial transport, respectively) (52, 53), did not cause reduction in cellubrevin levels on LBCs (Fig. 3A). Thus, induction of a maturation block alone, by causing stagnation of latex bead phagosomes, did not suffice to cause the appearance of Delta Cellubrevin on LBC (Fig. 3A) or reduction of cellubrevin levels in PNS.


View larger version (27K):
[in this window]
[in a new window]
  		Fig. 3.   Cellubrevin levels on phagosomes with pharmacologically induced maturation arrest. Western blot analysis of purified LBC from macrophages treated with brefeldin A, bafilomycin A, or nocodozole as described under "Experimental Procedures." A, J774 cells phagocytosed latex beads for 30 min in a synchronized infection, after which LBC were isolated from each sample. Equivalent amounts (protein) of phagosomes were separated by SDS-PAGE, transferred to Immobilon-P, and probed with antibodies against cellubrevin and SNAP 23. B, quantitative analysis of cellubrevin and SNAP 23 by Western blots. Cellubrevin levels on LBC purified from macrophages treated with solvent, BFA, bafilomycin, or nocodozole as described under "Experimental Procedures" were quantified as described in the legend to Fig. 1 (n = 3; *, p = 0.0001; ANOVA).

Brefeldin A Reduces Cellubrevin Levels on Phagosomes but Does Not Affect Cellubrevin Integrity-- In contrast to bafilomycin A and nocodozole, treatment with brefeldin A (BFA), an inhibitor of ARF GTPase-based vesicular trafficking within the secretory pathway, including the trafficking from the TGN, decreased levels of cellubrevin on LBC (Fig. 3, A and B). The effect was specific, as levels of SNAP 23 on LBC were not affected in BFA-treated cells (Fig. 3A). Cellubrevin levels were reduced on LBC by 75% in cells treated with BFA (p = 0.0001; ANOVA) (Fig. 3B). However, a cellubrevin degradation product was not detected on latex bead phagosomes in BFA-treated cells (Fig. 3A; Delta cellubrevin on MPC is shown for reference). Although cellubrevin levels were significantly reduced on LBCs in BFA-treated macrophages, overall cellular cellubrevin levels were not affected (Fig. 3A; PNS). It is possible that BFA effects on phagosome-associated cellubrevin were due to either its decreased delivery or increased removal from phagosomes. We favor the former possibility based on the following considerations: (i) cellubrevin has been implicated in TGN-to-endosome trafficking (45); (ii) it has been shown that the TGN t-SNARE syntaxin 6 can interact with cellubrevin (45); (iii) we have also found that syntaxin 6 is excluded from MPC, a phenomenon linked to the block in delivery of lysosomal effectors (e.g. H+ATPase and immature cathepsins) to phagosomes.2 As BFA has been shown to cause the tubulation and fusion of endosomes and TGN (48), this opens the theoretical possibility that BFA-mediated alterations in the protein profiles of LBC may be linked to mixing of compartments. However, since we observed a reduction rather than increase in phagosomal acquisition of cellubrevin, we can exclude the possibility that BFA in our experiments caused indiscriminant fusion of phagosomes with endosomes or TGN. Instead, the observed reduction of cellubrevin acquisition by LBC in BFA-treated cells is most likely associated with the disruption of phagosomal interactions with the endosomal and biosynthetic compartments.

Alterations in Cellubrevin Levels Correlate with Altered Recycling from Phagosomes-- We next tested whether alterations in cellubrevin levels affected recycling of markers from the phagosome. The effect of BFA (which lowers cellubrevin on phagosomes; Fig. 3) on recycling of transferrin receptor (TfR) from model phagosomes was examined. LBC were isolated from BFA-treated macrophages at 30 min post-phagocytosis. LBC from BFA-treated cells retained significantly more TfR relative to LBC from untreated control macrophages (p < 0.05; ANOVA) (Fig. 4, A and B). BFA treatment also caused increased levels of AP3 (p < 0.05; ANOVA), an adapter protein involved in TGN and endosomal trafficking (54) (Fig. 4, A and B). Similarly, levels of coronin, an actin-binding, general phagocytosis protein (also termed TACO, proposed to accumulate on mycobacterial phagosomes (28)), was moderately increased on LBC upon BFA treatment (p < 0.01; ANOVA) (Fig. 4, A and B). In contrast, levels of the early endosomal SNARE syntaxin 13 were not affected by BFA, suggesting that the effects seen with TfR, AP3, and coronin (Fig. 4, A and B) were not a result of indiscriminate membrane mixing.


View larger version (18K):
[in this window]
[in a new window]
  		Fig. 4.   Clearance of membrane-associated phagosomal markers during pharmacologically induced maturation block. J774 cells were treated with brefeldin A as described under "Experimental Procedures." Macrophages were allowed to phagocytose latex beads for 30 min in a synchronized infection after which LBC were isolated from each sample. Equivalent amounts (protein) of phagosomes were separated by SDS-PAGE, transferred to Immobilon-P, and probed with antibodies against transferrin receptor (TfR), adapter protein 3 (AP3, sigma 3), syntaxin 13, and coronin (also known as TACO). A, Western blot analysis. B, quantitative analysis of TfR, AP3, coronin, and syntaxin 13 by Western blots. Protein levels on LBC purified from macrophages treated with solvent, or BFA as described under "Experimental Procedures," were quantified as described in the legend to Fig. 1 (n = 3; *, p < 0.05; ANOVA).

MPC Retain Increased Levels of the ATPase NSF Involved in SNARE Priming-- After a round of membrane fusion is completed, SNARE proteins remain tightly associated in a cis-SNARE complex. SNARE molecules stored in cis complexes are made available for subsequent fusion events only upon a priming cycle, which involves an ATP-dependent disruption of the cis-SNARE aggregate. The priming process is dependent on the ATPase NSF association with SNARE complexes, via interactions that include another factor, alpha -SNAP (55). Upon ATP hydrolysis, the cis-SNARE complex is dissociated, and the primed free SNARE proteins become available for new docking and fusion events. Isolated phagosomes were probed for the presence of NSF and alpha -SNAP. Both MPC and LBC displayed membrane bound NSF and alpha -SNAP throughout the experiment with some evidence of reduced amounts as the maturation progressed (Fig. 5A). When NSF was examined at 24 and 72 h post-infection, we found that MPC retained significant levels of NSF, while most of it was lost from LBC (Fig. 5B).


View larger version (39K):
[in this window]
[in a new window]
  		Fig. 5.   NSF is retained on mycobacterial phagosomes. Western blot analysis of purified LBC and MPC from macrophages following synchronized infection after 10, 20, 40, and 60 min of phagocytosis (A) or 1 h of phagocytosis followed by chasing phagosomes for 24 h and 72 h (B). Equivalent amounts of phagosomes (5 µg of protein) were separated by SDS-PAGE, transferred to Immobilon-P, and probed with antibodies against NSF, alpha -SNAP, and Rab5.

LBC isolated from BFA-treated cells showed an increase in NSF levels (200%) relative to those isolated from untreated cells (p < 0.05; ANOVA) (Fig. 6, A and B). Inhibiting H+ATPase activity with bafilomycin A had a similar effect (p < 0.05; ANOVA) (Fig. 6, A and B). Nocodozole did not have an effect on NSF increase, and, if anything, it caused a slight reduction in NSF levels. Accumulation of NSF on LBC isolated from BFA-treated macrophages (Fig. 6) correlates with a marked reduction in cellubrevin levels (Fig. 3), while retention of NSF on MPC (Fig. 5) correlates with cellubrevin degradation. We interpret these observations as an impeded release of NSF from MPC due to disfunctional SNARE priming associated with either reduced levels of cellubrevin (e.g. as on BFA-treated LBC) or with a compromised physical integrity of this SNARE, as seen on mycobacterial phagosomes.


View larger version (21K):
[in this window]
[in a new window]
  		Fig. 6.   Effect of inhibitors of phagosomal maturation on NSF levels associated with phagosomes. A, Western blot analysis of purified LBC from macrophages treated with brefeldin A, bafilomycin A, or nocodozole as described under "Experimental Procedures." J774 cells phagocytosed latex beads for 30 min in a synchronized infection after which LBC were isolated from each sample. Equivalent amounts of phagosomes (5 µg of protein) or post-nuclear supernatant (PNS; 25 µg of protein) were separated by SDS-PAGE, transferred to Immobilon-P, and probed with antibodies against NSF and syntaxin 13. B, quantitative analysis of NSF and syntaxin 13 by Western blots. Protein levels on LBC purified from macrophages treated with solvent, BFA, bafilomycin, or nocodozole as described under "Experimental Procedures" were quantified as described in the legend to Fig. 1 (n = 3; *, p < 0.05; ANOVA).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The arrest of M. tuberculosis phagosome maturation has been associated with accumulation of Rab5 and exclusion of a number of regulatory factors: the Rab5 effector EEA1 (8) and the late endosomal GTPase Rab7 (19). These alterations are believed to lead to the paucity of the late endosomal lipid lysobisphosphatidic acid (8) and late endosomal/lysosomal enzymes, H+ATPase (29), cathepsin D (30, 31), and mannose 6-phosphate receptor (23). Here we have shown that mycobacteria affect the level and integrity of the v-SNARE Cellubrevin with repercussions for recycling of markers from the newly formed phagosomes and possibly of significance for interactions between the TGN and phagosomes. The generation of Delta cellubrevin on MPC can be attributed to either production of a protease by the mycobacteria targeting this host cell SNARE or can be ascribed to activation in infected cells of host homeostatic mechanisms degrading SNARE molecules (56).

The changes in cellubrevin levels and integrity are not the only alterations on mycobacterial phagosomes. Recently, we have reported the exclusion from MPC of the tethering molecule EEA1, a factor necessary for phagosome maturation (8). EEA1 is a major Rab5 effector implicated in vesicle tethering and fusion (57), including homotypic early endosomal fusion. The absence of EEA1 from MPC may appear counterintuitive, since it has been reported that MPC accumulate Rab5 (19), and Rab5 participates in the recruitment of EEA1 to endosomal membranes (58). However, EEA1 association with membranes depends on its FYVE domain binding to phosphatidylinositol 3-phosphate (59, 60) on the target organelles. The exclusion of EEA1 from MPC has been interpreted as interference with either generation or turnover of phosphatidylinositol 3-phosphate or blocking of EEA1 binding to the membrane of mycobacterial phagosomes (8, 61).

The alterations of cellubrevin on MPC most likely affect trafficking processes determining the maturation status of these phagosomes. While a role in interactions between phagosomes and endosomes cannot be excluded at present, we believe that cellubrevin may function on phagosomes in ways different from trafficking between endosomal organelles and phagosomes, a concept reinforced by the dispensability of cellubrevin in the context of early endosomal fusion (62). Cellubrevin and syntaxin 6 are the proposed cognate SNAREs (45), potentially involved in TGN-to-phagosome transport. The accumulation of cellubrevin over time on phagosomes, extending to the 24-h time point, is in keeping with cellubrevin playing a role in TGN-to-phagosome trafficking. In this context, the interaction of EEA1 with the t-SNARE syntaxin 6 is likely to be important in TGN-to-endosome trafficking (63). We interpret the effects of mycobacteria on cellubrevin presented here, EEA1 shown elsewhere (8), and on syntaxin 6,2 as a manifestation of convergent checkpoints involved in mycobacterial phagosome maturation arrest. Interference with the integrity or function of cellubrevin may thus represent a critical event in mycobacterial inhibition of phagosomal acquisition of lysosomal characteristics. In this model, the cleavage of cellubrevin, coupled with the exclusion of EEA1 from MPC, may inhibit interactions with syntaxin 6-containing TGN vesicles, thus deflecting the delivery of lysosomal enzymes by this route.

Cellubrevin may also play a role in the previously noted (24) partially defective recycling of plasma membrane markers associated with mycobacterial phagosomes. This phenomenon represents at present a less understood feature of mycobacterial phagosomes in the context of significance for intracellular survival. Previous studies have shown that mycobacterial phagosomes are accessible to transferrin, which can be chased out from these compartments (30, 64), but only at lower rates relative to model phagosomes containing beads (30, 64). This suggests that TfR recycling on MPC is affected, albeit not completely abrogated. The partial defect in TfR recycling corresponds with our observation that, although a substantial portion of cellubrevin is truncated on mycobacterial phagosomes, some amount of full-length protein remains on MPC at all times. In this context, it is worth noting that two toxin-insensitive VAMPs, such as VAMP7 and endobrevin (VAMP8), overlapping with TfR-containing recycling vesicles, are also present on endosomes and phagosomes (65, 66). Thus, cellubrevin function in recycling may not be completely abrogated on MPC, but instead, its lower amounts, with or without participation of other VAMPs, may function at subopitmal levels, which in turn could be important in maintaining the specialized mycobacterial phagosome.

An alternative interpretation for the effect BFA on the phagosome remodeling could involve the delivery of cellubrevin to the plasma membrane. Cellubrevin has been shown to localize to nascent phagocytic cups (4) and has been suggested to facilitate the delivery of membrane at the site of phagocytosis. Hackam et al. (67) have reported that treating cells with BFA inhibits the fusion of cellubrevin containing endosomes with the plasma membrane. Thus, it is conceivable that the effects caused by BFA in our hands could reflect a reduced delivery of cellubrevin containing membranes to the site of phagosome formation. However, BFA concentrations used by Hackam et al. (67) were much higher (6-fold) than those applied in our work and exceed the BFA concentration required for TGN disruption (68). Thus, it is likely that the effects of BFA on cellubrevin levels on LBC seen in our work are linked to disruption of phagosomal interactions with other compartments, rather than effects on cellubrevin redistribution with indirect consequences for phagosomes.

We envision two different mechanisms to explain the appearance of Delta cellubrevin on mycobacterial phagosomes: (i) proteolytic attack by a mycobacterial product or (ii) recruitment of host cytosolic enzymes degrading cellubrevin. Since M. tuberculosis produces at least two putative metalloproteases and contains other secreted hydrolases (69), it is possible that M. tuberculosis may directly target and proteolytically degrade Cellubrevin, similar to the action of clostridial metalloproteases, the tetanus and botulinum toxins (70). Alternatively, mycobacteria may recruit or activate host cell SNARE proteolytic machinery (56). Although Delta cellubrevin on MPC most likely lacks the transmembrane domain, it is probably retained by association with other SNAREs in a binary complex or in the ternary cis-SNARE complex that can no longer be primed, as evidenced by accumulation of NSF on MPC. The role of NSF in phagosome maturation has been suggested by Funato et al. (71), and alterations in its amounts on phagosomes of other pathogens have been reported (72). Palade and colleagues (73) have recently described the presence of a large protein and polar lipid complex, which contains cellubrevin as well as Rab5, NSF, alpha -SNAP, syntaxin, dynamin, caveolin, and cholesterol. Mycobacterial phagosomes also contain caveolin and dynamin.2 We predict the presence of a similar complex on phagosomes, which is further modified on MPC by cellubrevin proteolysis. The observed truncation of cellubrevin on MPC is most likely involved in the long term maintenance of the specialized mycobacterial phagosomal compartment in macrophages.

    ACKNOWLEDGEMENTS

We thank J. Bonifacino, P. DeCamilli, E. Dell'Angelica, W. Hong, L. Huber, J. Pieters, R. Prekeris, P. Roche, R. Scheller, and S. Whiteheart for antibodies.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant AI45148.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

** To whom correspondence should be addressed: University of New Mexico School of Medicine, Dept. of Molecular Genetics and Microbiology, 915 Camino de Salud NE, Albuquerque, NM 87131. Tel.: 505-272-0291; Fax: 505-272-6029; E-mail: vderetic@salud.unm.edu.

Published, JBC Papers in Press, February 1, 2002, DOI 10.1074/jbc.M200335200

2 R. A. Fratti and V. Deretic, unpublished results.

    ABBREVIATIONS

The abbreviations used are: MPC, M. tuberculosis phagosomal compartment(s); BFA, brefeldin A; LBC, latex bead phagosomal compartment(s); NSF, N-ethylmaleimide-sensitive factor, PNS, postnuclear supernatant(s); SNAP, soluble NSF adapter protein; SNARE, SNAP receptor(s); TGN, trans-Golgi network; TfR, transferrin receptor; VAMP, vesicle-associated membrane protein; BCG, M. tuberculosis var. bovis BCG Pasteur; ANOVA, analysis of variance; m.o.i., multiplicity of infections.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Alvarez-Dominguez, C., Barbieri, A. M., Beron, W., Wandinger-Ness, A., and Stahl, P. D. (1996) J. Biol. Chem. 271, 13834-13843[Abstract/Free Full Text]
2. Alvarez-Dominguez, C., Roberts, R., and Stahl, P. D. (1997) J. Cell Sci. 110, 731-743[Abstract]
3. Alvarez-Dominguez, C., and Stahl, P. D. (1999) J. Biol. Chem. 274, 11459-11462[Abstract/Free Full Text]
4. Bajno, L., Peng, X. R., Schreiber, A. D., Moore, H. P., Trimble, W. S., and Grinstein, S. (2000) J. Cell Biol. 149, 697-706[Abstract/Free Full Text]
5. Botelho, R. J., Hackam, D. J., Schreiber, A. D., and Grinstein, S. (2000) J. Biol. Chem. 275, 15717-15727[Abstract/Free Full Text]
6. Defacque, H., Egeberg, M., Habermann, A., Diakonova, M., Roy, C., Mangeat, P., Voelter, W., Marriott, G., Pfannstiel, J., Faulstich, H., and Griffiths, G. (2000) EMBO J. 19, 199-212[CrossRef][Medline] [Order article via Infotrieve]
7. Downey, G. P., Botelho, R. J., Butler, J. R., Moltyaner, Y., Chien, P., Schreiber, A. D., and Grinstein, S. (1999) J. Biol. Chem. 274, 28436-28444[Abstract/Free Full Text]
8. Fratti, R. A., Backer, J. M., Gruenberg, J., Corvera, S., and Deretic, V. (2001) J. Cell Biol. 154, 631-644[Abstract/Free Full Text]
9. Jahraus, A., Tjelle, T. E., Berg, T., Habermann, A., Storrie, B., Ulrich, O., and Griffiths, G. (1998) J. Biol. Chem. 273, 30379-30390[Abstract/Free Full Text]
10. Hackstadt, T. (2000) Traffic 1, 93-99[CrossRef][Medline] [Order article via Infotrieve]
11. Cossart, P., and Bierne, H. (2001) Curr. Opin. Immunol. 13, 96-103[CrossRef][Medline] [Order article via Infotrieve]
12. Smith, G. A., and Portnoy, D. A. (1997) Trends Microbiol. 5, 272-276[CrossRef][Medline] [Order article via Infotrieve]
13. Teysseire, N., Boudier, J. A., and Raoult, D. (1995) Infect. Immun. 63, 366-374[Abstract]
14. Chakraborty, P., Sturgill-Koszycki, S., and Russell, D. G. (1994) Methods Cell Biol. 45, 261-276[Medline] [Order article via Infotrieve]
15. Meresse, S., Steele-Mortimer, O., Finlay, B. B., and Gorvel, J. P. (1999) EMBO J. 18, 4394-4403[CrossRef][Medline] [Order article via Infotrieve]
16. Meresse, S., Steele-Mortimer, O., Moreno, E., Desjardins, M., Finlay, B., and Gorvel, J. P. (1999) Nat. Cell Biol. 1, E183-E188[CrossRef][Medline] [Order article via Infotrieve]
17. Russell, D. G., Xu, S., and Chakraborty, P. (1992) J. Cell Sci. 103, 1193-1210[Abstract/Free Full Text]
18. Scidmore, M. A., Fischer, E. R., and Hackstadt, T. (1996) J. Cell Biol. 134, 363-374[Abstract/Free Full Text]
19. Via, L. E., Deretic, D., Ulmer, R. J., Hibler, N. S., Huber, L. A., and Deretic, V. (1997) J. Biol. Chem. 272, 13326-13331[Abstract/Free Full Text]
20. Vazquez-Torres, A., Fantuzzi, G., Edwards, C. K., III, Dinarello, C. A., and Fang, F. C. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 2561-2565[Abstract/Free Full Text]
21. Ullrich, H. J., Beatty, W. L., and Russell, D. G. (2000) J. Immunol. 165, 6073-6080[Abstract/Free Full Text]
22. Fratti, R. A., Vergne, I., Chua, J., Skidmore, J., and Deretic, V. (2000) Electrophoresis 21, 3378-3385[CrossRef][Medline] [Order article via Infotrieve]
23. Xu, S., Cooper, A., Sturgill-Koszycki, S., van Heyningen, T., Chatterjee, D., Orme, I., Allen, P., and Russell, D. G. (1994) J. Immunol. 153, 2568-2578[Abstract]
24. Clemens, D. L., and Horwitz, M. A. (1995) J. Exp. Med. 181, 257-270[Abstract/Free Full Text]
25. de Chastellier, C., Lang, T., and Thilo, L. (1995) Eur. J. Cell Biol. 68, 167-182[Medline] [Order article via Infotrieve]
26. Deretic, V., and Fratti, R. A. (1999) Mol. Microbiol. 31, 1603-1609[CrossRef][Medline] [Order article via Infotrieve]
27. Armstrong, J. A., and Hart, P. D. (1971) J. Exp. Med. 134, 713-740[Abstract]
28. Ferrari, G., Langen, H., Naito, M., and Pieters, J. (1999) Cell 97, 435-447[CrossRef][Medline] [Order article via Infotrieve]
29. Sturgill-Koszycki, S., Schlesinger, P. H., Chakraborty, P., Haddix, P. L., Collins, H. L., Fok, A. K., Allen, R. D., Gluck, S. L., Heuser, J., and Russell, D. G. (1994) Science 263, 678-681[Abstract/Free Full Text]
30. Sturgill-Koszycki, S., Schaible, U. E., and Russell, D. G. (1996) EMBO J. 15, 6960-6968[Medline] [Order article via Infotrieve]
31. Malik, Z. A., Iyer, S. S., and Kusner, D. J. (2001) J. Immunol. 166, 3392-3401[Abstract/Free Full Text]
32. Weber, T., Zemelman, B. V., McNew, J. A., Westermann, B., Gmachl, M., Parlati, F., Sollner, T. H., and Rothman, J. E. (1998) Cell 92, 759-772[CrossRef][Medline] [Order article via Infotrieve]
33. Block, M. R., Glick, B. S., Wilcox, C. A., Wieland, F. T., and Rothman, J. E. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 7852-7856[Abstract/Free Full Text]
34. Clary, D. O., Griff, I. C., and Rothman, J. E. (1990) Cell 61, 709-721[CrossRef][Medline] [Order article via Infotrieve]
35. Sollner, T., Whiteheart, S. W., Brunner, M., Erdjument-Bromage, H., Geromanos, S., Tempst, P., and Rothman, J. E. (1993) Nature 362, 318-324[CrossRef][Medline] [Order article via Infotrieve]
36. Fukuda, R., McNew, J. A., Weber, T., Parlati, F., Engel, T., Nickel, W., Rothman, J. E., and Sollner, T. H. (2000) Nature 407, 198-202[CrossRef][Medline] [Order article via Infotrieve]
37. Parlati, F., McNew, J. A., Fukuda, R., Miller, R., Sollner, T. H., and Rothman, J. E. (2000) Nature 407, 194-198[CrossRef][Medline] [Order article via Infotrieve]
38. McNew, J. A., Parlati, F., Fukuda, R., Johnston, R. J., Paz, K., Paumet, F., Sollner, T. H., and Rothman, J. E. (2000) Nature 407, 153-159[CrossRef][Medline] [Order article via Infotrieve]
39. Sogaard, M., Tani, K., Ye, R. R., Geromanos, S., Tempst, P., Kirchhausen, T., Rothman, J. E., and Sollner, T. (1994) Cell 78, 937-948[CrossRef][Medline] [Order article via Infotrieve]
40. Lupashin, V. V., and Waters, M. G. (1997) Science 276, 1255-1258[Abstract/Free Full Text]
41. McBride, H. M., Rybin, V., Murphy, C., Giner, A., Teasdale, R., and Zerial, M. (1999) Cell 98, 377-386[CrossRef][Medline] [Order article via Infotrieve]
42. VanRheenen, S. M., Cao, X., Sapperstein, S. K., Chiang, E. C., Lupashin, V. V., Barlowe, C., and Waters, M. G. (1999) J. Cell Biol. 147, 729-742[Abstract/Free Full Text]
43. Cao, X., and Barlowe, C. (2000) J. Cell Biol. 149, 55-66[Abstract/Free Full Text]
44. Galli, T., Chilcote, T., Mundigl, O., Binz, T., Niemann, H., and De Camilli, P. (1994) J. Cell Biol. 125, 1015-1024[Abstract/Free Full Text]
45. Bock, J. B., Klumperman, J., Davanger, S., and Scheller, R. H. (1997) Mol. Biol. Cell 8, 1261-1271[Abstract]
46. Dhandayuthapani, S., Via, L. E., Thomas, C. A., Horowitz, P. M., Deretic, D., and Deretic, V. (1995) Mol. Microbiol. 17, 901-912[CrossRef][Medline] [Order article via Infotrieve]
47. Desjardins, M., Huber, L. A., Parton, R. G. F., and Griffiths, G. (1994) J. Cell Biol. 124, 677-688[Abstract/Free Full Text]
48. Lippincott-Schwartz, J., Yuan, L., Tipper, C., Amherdt, M., Orci, L., and Klausner, R. D. (1991) Cell 67, 601-616[CrossRef][Medline] [Order article via Infotrieve]
49. Via, L. E., Fratti, R. A., McFalone, M., Pagan-Ramos, E., Deretic, D., and Deretic, V. (1998) J. Cell Sci. 111, 897-905[Abstract]
50. Advani, R. J., Yang, B., Prekeris, R., Lee, K. C., Klumperman, J., and Scheller, R. H. (1999) J. Cell Biol. 146, 765-776[Abstract/Free Full Text]
51. McMahon, H. T., Ushkaryov, Y. A., Edelmann, L., Link, E., Binz, T., Niemann, H., Jahn, R., and Sudhof, T. C. (1993) Nature 364, 346-349[CrossRef][Medline] [Order article via Infotrieve]
52. van Deurs, B., Holm, P. K., Kayser, L., and Sandvig, K. (1995) Eur. J. Cell Biol. 66, 309-323[Medline] [Order article via Infotrieve]
53. van Weert, A. W., Dunn, K. W., Gueze, H. J., Maxfield, F. R., and Stoorvogel, W. (1995) J. Cell Biol. 130, 821-834[Abstract/Free Full Text]
54. Faundez, V., Horng, J. T., and Kelly, R. B. (1998) Cell 93, 423-432[CrossRef][Medline] [Order article via Infotrieve]
55. Banerjee, A., Barry, V. A., DasGupta, B. R., and Martin, T. F. J. (1996) J. Biol. Chem. 271, 20223-20226[Abstract/Free Full Text]
56. Bryant, N. J., and James, D. E. (2001) EMBO J. 20, 3380-3388[CrossRef][Medline] [Order article via Infotrieve]
57. Nielsen, E., Severin, F., Backer, J. M., Hyman, A. A., and Zerial, M. (1999) Nat. Cell Biol. 1, 376-382[CrossRef][Medline] [Order article via Infotrieve]
58. Simonsen, A., Lippe, R., Christoforidis, S., Gaullier, J. M., Brech, A., Callaghan, J., Toh, B. H., Murphy, C., Zerial, M., and Stenmark, H. (1998) Nature 394, 494-498[CrossRef][Medline] [Order article via Infotrieve]
59. Gaullier, J. M., Ronning, E., Gillooly, D. J., and Stenmark, H. (2000) J. Biol. Chem. 275, 24595-24600[Abstract/Free Full Text]
60. Patki, V., Virbasius, J., Lane, W. S., Toh, B. H., Shpetner, H. S., and Corvera, S. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 7326-7330[Abstract/Free Full Text]
61. Gillooly, D. J., Simonsen, A., and Stenmark, H. (2001) J. Cell Biol. 155, 15-17[Abstract/Free Full Text]
62. Link, E., McMahon, H., Fischer von Mollard, G., Yamasaki, S., Niemann, H., Sudhof, T. C., and Jahn, R. (1993) J. Biol. Chem. 268, 18423-18426[Abstract/Free Full Text]
63. Simonsen, A., Gaullier, J. M., D'Arrigo, A., and Stenmark, H. (1999) J. Biol. Chem. 274, 28857-28860[Abstract/Free Full Text]
64. Clemens, D. L., and Horwitz, M. A. (1996) J. Exp. Med. 184, 1349-1355[Abstract/Free Full Text]
65. Wong, S. H., Zhang, T., Xu, Y., Subramaniam, V. N., Griffiths, G., and Hong, W. (1998) Mol. Biol. Cell 9, 1549-1563[Abstract/Free Full Text]
66. Galli, T., Zahraoui, A., Vaidyanathan, V. V., Raposo, G., Tian, J. M., Karin, M., Niemann, H., and Louvard, D. (1998) Mol. Biol. Cell 9, 1437-1448[Abstract/Free Full Text]
67. Hackam, D. J., Botelho, R. J., Sjolin, C., Rotstein, O. D., Robinson, J. M., Schreiber, A. D., and Grinstein, S. (2001) J. Biol. Chem. 276, 18200-18208[Abstract/Free Full Text]
68. Lippincott-Schwartz, J., Yuan, L. C., Bonifacino, J. S., and Klausner, R. D. (1989) Cell 56, 801-813[CrossRef][Medline] [Order article via Infotrieve]
69. Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S., Barry, C. E., III, Tekaia, F., Badcock, K., Basham, D., Brown, D., Chillingworth, T., Connor, R., Davies, R., Devlin, K., Feltwell, T., Gentles, S., Hamlin, N., Holroyd, S., Hornsby, T., Jagels, K., Barrell, B. G., et al.. (1998) Nature 393, 537-544[CrossRef][Medline] [Order article via Infotrieve]
70. Montecucco, C., and Schiavo, G. (1994) Mol. Microbiol. 13, 1-8[Medline] [Order article via Infotrieve]
71. Funato, K., Beron, W., Yang, C. Z., Mukhopadhyay, A., and Stahl, P. D. (1997) J. Biol. Chem. 272, 16147-16151[Abstract/Free Full Text]
72. Mukherjee, K., Siddiqi, S. A., Hashim, S., Raje, M., Basu, S. K., and Mukhopadhyay, A. (2000) J. Cell Biol. 148, 741-753[Abstract/Free Full Text]
73. Predescu, S. A., Predescu, D. N., and Palade, G. E. (2001) Mol. Biol. Cell 12, 1019-1033[Abstract/Free Full Text]

Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Infect. Immun.Home page
A. M. Firoved, W. Ornatowski, and V. Deretic
Microarray Analysis Reveals Induction of Lipoprotein Genes in Mucoid Pseudomonas aeruginosa: Implications for Inflammation in Cystic Fibrosis
Infect. Immun., September 1, 2004; 72(9): 5012 - 5018.
[Abstract] [Full Text] [PDF]

Home page
 J. Bacteriol.Home page
T. Douglas, D. S. Daniel, B. K. Parida, C. Jagannath, and S. Dhandayuthapani
Methionine Sulfoxide Reductase A (MsrA) Deficiency Affects the Survival of Mycobacterium smegmatis within Macrophages
J. Bacteriol., June 1, 2004; 186(11): 3590 - 3598.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
O. V. Vieira, R. E. Harrison, C. C. Scott, H. Stenmark, D. Alexander, J. Liu, J. Gruenberg, A. D. Schreiber, and S. Grinstein
Acquisition of Hrs, an Essential Component of Phagosomal Maturation, Is Impaired by Mycobacteria
Mol. Cell. Biol., May 15, 2004; 24(10): 4593 - 4604.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
B. H. Miller, R. A. Fratti, J. F. Poschet, G. S. Timmins, S. S. Master, M. Burgos, M. A. Marletta, and V. Deretic
Mycobacteria Inhibit Nitric Oxide Synthase Recruitment to Phagosomes during Macrophage Infection
Infect. Immun., May 1, 2004; 72(5): 2872 - 2878.
[Abstract] [Full Text] [PDF]